New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, October 2024.

Autor: Schillie S, Loehr J, Chen WH, Moser CA, Cooper G, Isenhour C, McNamara LA
Jazyk: angličtina
Zdroj: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Dec 12; Vol. 73 (49), pp. 1124-1128. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.15585/mmwr.mm7349a3
Abstrakt: Two meningococcal serogroup B vaccines are licensed for use in the United States. In August 2024, the Food and Drug Administration (FDA) changed the label for the meningococcal serogroup B MenB-4C vaccine (Bexsero) from a 2-dose schedule (intervals of 0 and ≥1 month) to a 2-dose schedule (0 and 6 months) and added a 3-dose schedule (0, 1-2, and 6 months), based on new immunogenicity data. On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) voted to update its recommendations for the MenB-4C dosing interval and schedule to align with the new FDA label. ACIP recommends extending the interval for the 2-dose series of MenB-4C from 0 and ≥1 month to 0 and 6 months for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making and has added a recommendation for a 3-dose series with doses administered at 0, 1-2, and 6 months for persons aged ≥10 years at increased risk. The updated ACIP recommendations for MenB-4C align with existing ACIP recommendations for the other FDA-licensed meningococcal serogroup B vaccine, MenB-FHbp (Trumenba).
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Charlotte A. Moser reports receipt of an advance from Columbia University Press for co-authoring “Vaccines and Your Family: Separating Fact from Fiction” in 2024. No other potential conflicts of interest were disclosed.
Databáze: MEDLINE
Externí odkaz: